Information Provided By:
Fly News Breaks for May 3, 2018
ABMD
May 3, 2018 | 11:50 EDT
Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $360 saying this morning's Q4 results easily beat his estimates. The momentum in using Impella to treat patients "remains strong" and there are new products and geographies that should continue to drive sales, O'Brien tells investors in a post-earnings research note. The analyst, while admitting the valuation is "hefty," reiterates an Overweight rating on Abiomed. He continues to encourage investors to own the name.
News For ABMD From the Last 2 Days
There are no results for your query ABMD